NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Humans Remove constraint Subjects: Humans Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

1401. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry

1402. FDA categorization of investigational device exemption (IDE) devices to assist the Centers for Medicare and Medicaid Services (CMS) with coverage decisions: guidance for sponsors, clinical investigators, industry, institutional review boards, and Food and Drug Administration staff

1403. Technical considerations for additive manufactured medical devices: guidance for industry and Food and Drug Administration staff

1404. Use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components

1405. Software as a medical device (SAMD): clinical evaluation : guidance for industry and Food and Drug Administration staff

1407. Systemic antibacterial and antifungal drugs: susceptibility test interpretive criteria labeling for NDAs and ANDAs

1408. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system

1409. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

1410. Unique device identification: policy regarding compliance dates for class I and unclassified devices : immediately in effect guidance for industry and Food and Drug Administration staff